Aurinia’s Dosing Patent For Lupkynis A ‘Slippery Slope’ To Extending US Market Exclusivity?
The Institute for Clinical and Economic Review raises concerns about the cost implications of companies obtaining extended market exclusivity by patenting the treatment protocol used for drugs in clinical trials.
You may also be interested in...
If pharma got to choose, it would pick the bills that seek to discourage price increases instead of the ones that allow the government to negotiate drug prices or use international reference pricing. It is unclear whether any legislation will pass, but without a Republican majority in the Senate, the risk for industry has never been greater.
GSK's Benlysta and Aurinia's Lupkynis for lupus nephritis are priced in line with the drug pricing watch dog's health benefit price benchmark ranges.
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.